16 September 2024
A study from the School of Veterinary Medicine has identified potential new treatments for feline infectious peritonitis (FIP), a fatal disease affecting cats. Published in the scientific journal Veterinary Sciences, the research, led by faculty members Drs Manos Vlasiou, Georgios Nikolaou, Kyriakos Spanoudes, and Daphne Mavrides, explores the use of vitamin E compounds to inhibit a key viral enzyme.
FIP is caused by a feline coronavirus and is almost always fatal once symptoms appear. The study focused on two forms of vitamin E, β-tocotrienol and δ-tocotrienol, which were found to interact with the virus’s main protease, an enzyme crucial for the virus’s replication. Using computer simulations, the researchers discovered that these compounds could potentially block the enzyme, opening up new avenues for treatment.
First author Dr Manos Vlasiou stated, ‘Our findings suggest that β-tocotrienol and δ-tocotrienol could serve as promising candidates for developing new treatments against FIP. By targeting the virus’s main protease, these compounds may help inhibit viral replication and improve outcomes for affected cats’.
The study’s findings are significant because they suggest that these vitamin E analogs could be developed into drugs to combat FIP or used alongside existing treatments. The research is still in its early stages, but it provides a promising new direction for managing this disease.
The team used computer-aided drug discovery techniques to simulate how these compounds interact with the virus at a molecular level. This approach allows for rapid screening of potential treatments, saving time and resources compared to traditional methods.
While further research, including laboratory and clinical trials, is needed to confirm these findings, the study offers hope for improving the prognosis for cats suffering from FIP. The potential use of vitamin E compounds could lead to more effective treatments and better outcomes for affected cats.